NASDAQ:AGIO - Agios Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $67.10
  • Forecasted Upside: 18.05 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$56.84
▼ -4.43 (-7.23%)

This chart shows the closing price for AGIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agios Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGIO

Analyst Price Target is $67.10
▲ +18.05% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Agios Pharmaceuticals in the last 3 months. The average price target is $67.10, with a high forecast of $88.00 and a low forecast of $50.00. The average price target represents a 18.05% upside from the last price of $56.84.

This chart shows the closing price for AGIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Agios Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2021OppenheimerReiterated RatingHoldLow
6/10/2021HC WainwrightInitiated CoverageBuy$88.00Low
4/30/2021The Goldman Sachs GroupInitiated CoverageNeutralMedium
4/30/2021Canaccord GenuityBoost Price TargetBuy$57.00 ➝ $65.00Low
4/30/2021BarclaysBoost Price TargetPositive ➝ Overweight$65.00 ➝ $70.00Low
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$54.00Medium
3/4/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$55.00 ➝ $50.00High
3/1/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
3/1/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$64.00 ➝ $54.00Low
2/26/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$55.00 ➝ $50.00High
1/27/2021SVB LeerinkBoost Price TargetOutperform$51.00 ➝ $55.00High
1/27/2021BarclaysBoost Price TargetPositive ➝ Overweight$58.00 ➝ $65.00High
1/14/2021BarclaysBoost Price Target$50.00 ➝ $58.00Medium
12/28/2020Canaccord GenuityLower Price TargetBuy$70.00 ➝ $57.00N/A
12/22/2020SVB LeerinkLower Price Target$61.00 ➝ $51.00High
12/22/2020Royal Bank of CanadaLower Price Target$59.00 ➝ $66.00Medium
12/21/2020Piper SandlerBoost Price Target$73.00 ➝ $80.00Low
12/9/2020BMO Capital MarketsLower Price Target$57.00 ➝ $50.00High
12/9/2020SVB LeerinkLower Price TargetOutperform$67.00 ➝ $61.00High
11/20/2020BarclaysBoost Price TargetOverweight$46.00 ➝ $50.00High
11/19/2020Cantor FitzgeraldBoost Price TargetOverweight$68.00 ➝ $79.00High
10/22/2020BarclaysUpgradeEqual Weight ➝ Overweight$46.00High
10/19/2020Needham & Company LLCLower Price TargetBuy$71.00 ➝ $69.00Low
10/19/2020SVB LeerinkLower Price TargetPositive ➝ Outperform$72.00 ➝ $67.00Medium
10/19/2020Piper SandlerLower Price TargetOverweight$80.00 ➝ $73.00Medium
10/19/2020Canaccord GenuityReiterated RatingBuy$72.00 ➝ $70.00Medium
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$70.00 ➝ $72.00High
7/31/2020Canaccord GenuityReiterated RatingBuy$72.00High
7/30/2020Needham & Company LLCInitiated CoverageBuy$71.00High
6/15/2020SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $72.00Medium
6/15/2020GuggenheimBoost Price TargetBuy$60.00 ➝ $66.00Medium
6/15/2020CitigroupBoost Price TargetBuy$64.00 ➝ $75.00Medium
6/15/2020OppenheimerReiterated RatingHoldMedium
6/12/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $80.00High
5/4/2020JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $82.00High
5/1/2020Canaccord GenuityReiterated RatingBuy$72.00High
4/30/2020OppenheimerReiterated RatingHoldHigh
4/30/2020Needham & Company LLCReiterated RatingBuy$71.00Low
3/4/2020BarclaysInitiated CoverageEqual Weight$50.00High
3/4/2020CowenReiterated RatingBuyHigh
2/17/2020Needham & Company LLCReiterated RatingBuy$71.00High
2/14/2020Cantor FitzgeraldReiterated RatingOverweight$64.00 ➝ $70.00High
2/13/2020CowenReiterated RatingBuyHigh
2/13/2020OppenheimerReiterated RatingHoldHigh
1/31/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
1/21/2020OppenheimerReiterated RatingHoldLow
1/14/2020CowenReiterated RatingBuyHigh
12/10/2019CowenReiterated RatingBuyLow
12/9/2019BMO Capital MarketsBoost Price TargetOutperform$45.00 ➝ $49.00High
12/4/2019JPMorgan Chase & Co.Lower Price TargetOverweight$80.00 ➝ $68.00High
11/26/2019Cantor FitzgeraldInitiated CoverageOverweight$64.00Medium
11/5/2019CitigroupLower Price TargetBuy$80.00 ➝ $64.00High
11/1/2019Royal Bank of CanadaSet Price TargetBuy$79.00N/A
10/31/2019Needham & Company LLCReiterated RatingBuy$71.00High
10/28/2019Piper Jaffray CompaniesLower Price TargetOverweight$80.00 ➝ $70.00High
10/1/2019Royal Bank of CanadaLower Price TargetOutperform$82.00High
9/30/2019CowenReiterated RatingBuyHigh
9/24/2019Piper Jaffray CompaniesSet Price TargetBuy$80.00Medium
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$55.00Low
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$45.00Low
8/2/2019Royal Bank of CanadaSet Price TargetBuy$89.00Medium
5/31/2019CowenReiterated RatingBuyHigh
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$55.00Medium
5/16/2019Royal Bank of CanadaBoost Price Target$90.00High
5/16/2019CowenReiterated RatingBuyHigh
5/3/2019Piper Jaffray CompaniesLower Price TargetOverweight$100.00 ➝ $85.00High
3/13/2019CowenReiterated RatingBuyHigh
2/20/2019OppenheimerReiterated RatingMarket PerformLow
2/15/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$80.00High
2/14/2019Piper Jaffray CompaniesLower Price TargetOverweight$100.00High
11/16/2018OppenheimerReiterated RatingHoldLow
11/2/2018CowenReiterated RatingBuyMedium
11/1/2018OppenheimerReiterated RatingHoldHigh
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$80.00Low
9/17/2018GuggenheimInitiated CoverageNeutralLow
9/5/2018Canaccord GenuityReiterated RatingBuy$90.00High
8/2/2018Needham & Company LLCReiterated RatingBuyHigh
8/2/2018Canaccord GenuityReiterated RatingBuyHigh
8/2/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
7/23/2018SunTrust BanksReiterated RatingBuy$123.00Low
6/4/2018Piper Jaffray CompaniesReiterated RatingBuyLow
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight$125.00High
5/23/2018CitigroupInitiated CoverageBuy$117.00High
5/7/2018Credit Suisse GroupSet Price TargetBuy$95.00Low
5/7/2018SunTrust BanksSet Price TargetBuy ➝ Buy$115.00Medium
4/11/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$80.00 ➝ $95.00Medium
2/15/2018SunTrust BanksReiterated RatingBuy ➝ Buy$80.00 ➝ $101.00Low
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$76.00 ➝ $85.00Low
2/15/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $80.00Low
2/15/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$72.00 ➝ $86.00Low
2/14/2018OppenheimerDowngradeOutperform ➝ Market PerformLow
2/14/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
1/18/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00Medium
1/1/2018OppenheimerSet Price TargetBuy$83.00High
12/26/2017OppenheimerSet Price TargetBuy$83.00Low
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00High
12/11/2017OppenheimerReiterated RatingBuy$83.00Low
11/19/2017SunTrust BanksSet Price TargetBuy$80.00N/A
11/17/2017OppenheimerSet Price TargetBuy$83.00N/A
11/2/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 ➝ $66.00N/A
10/4/2017SunTrust BanksReiterated RatingBuy$80.00N/A
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$78.00High
8/10/2017OppenheimerReiterated RatingOutperform$75.00 ➝ $83.00Low
8/10/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$54.00 ➝ $72.00Medium
8/8/2017Canaccord GenuitySet Price TargetBuy$90.00Low
8/8/2017SunTrust BanksReiterated RatingBuy ➝ Buy$68.00 ➝ $80.00Low
8/2/2017Canaccord GenuitySet Price TargetBuy$90.00Medium
8/2/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$50.00 ➝ $80.00High
8/1/2017Janney Montgomery ScottReiterated RatingHoldHigh
6/26/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
6/11/2017OppenheimerSet Price TargetBuy$75.00Medium
6/1/2017OppenheimerSet Price TargetBuy$75.00Low
5/18/2017Canaccord GenuitySet Price TargetBuy$90.00Medium
5/4/2017Canaccord GenuitySet Price TargetBuy$90.00High
4/18/2017Credit Suisse GroupReiterated RatingOutperform$61.00High
3/1/2017OppenheimerSet Price TargetBuy$75.00N/A
2/16/2017Canaccord GenuitySet Price TargetBuy$90.00N/A
2/16/2017OppenheimerSet Price TargetBuy$75.00N/A
2/16/2017CowenReiterated RatingBuyN/A
2/16/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$57.00N/A
1/17/2017CIBCUpgradeMarket Perform ➝ OutperformN/A
1/17/2017OppenheimerUpgradeMarket Perform ➝ Outperform$75.00N/A
1/9/2017CowenReiterated RatingBuyN/A
1/9/2017OppenheimerReiterated RatingHoldN/A
1/3/2017OppenheimerReiterated RatingHoldN/A
12/19/2016SVB LeerinkReiterated RatingMarket Perform$56.00 ➝ $45.00N/A
12/18/2016OppenheimerReiterated RatingHoldN/A
12/18/2016Canaccord GenuitySet Price TargetBuy$90.00N/A
12/16/2016Needham & Company LLCReiterated RatingBuy$60.00 ➝ $54.00N/A
12/7/2016Needham & Company LLCReiterated RatingBuy$60.00N/A
12/5/2016Canaccord GenuityReiterated RatingBuy$90.00N/A
11/29/2016OppenheimerInitiated CoverageMarket PerformN/A
11/21/2016Credit Suisse GroupReiterated RatingBuyN/A
11/4/2016SVB LeerinkReiterated RatingMarket PerformN/A
11/3/2016CowenReiterated RatingBuyN/A
10/24/2016Needham & Company LLCInitiated CoverageBuy$60.00N/A
9/8/2016Canaccord GenuityReiterated RatingBuy$90.00N/A
8/19/2016BTIG ResearchInitiated CoverageNeutralN/A
8/10/2016The Goldman Sachs GroupReiterated RatingNeutral$46.00N/A
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
(Data available from 6/22/2016 forward)
Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $56.84
Low: $56.67
High: $61.28

50 Day Range

MA: $56.30
Low: $52.06
High: $61.27

52 Week Range

Now: $56.84
Low: $32.47
High: $62.15

Volume

715,753 shs

Average Volume

694,454 shs

Market Capitalization

$3.50 billion

P/E Ratio

2.49

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Agios Pharmaceuticals?

The following Wall Street research analysts have issued reports on Agios Pharmaceuticals in the last twelve months: Barclays PLC, BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for AGIO.

What is the current price target for Agios Pharmaceuticals?

10 Wall Street analysts have set twelve-month price targets for Agios Pharmaceuticals in the last year. Their average twelve-month price target is $67.10, suggesting a possible upside of 18.1%. HC Wainwright has the highest price target set, predicting AGIO will reach $88.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $50.00 for Agios Pharmaceuticals in the next year.
View the latest price targets for AGIO.

What is the current consensus analyst rating for Agios Pharmaceuticals?

Agios Pharmaceuticals currently has 4 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGIO will outperform the market and that investors should add to their positions of Agios Pharmaceuticals.
View the latest ratings for AGIO.

What other companies compete with Agios Pharmaceuticals?

How do I contact Agios Pharmaceuticals' investor relations team?

Agios Pharmaceuticals' physical mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is 617-649-8600 and its investor relations email address is [email protected] The official website for Agios Pharmaceuticals is www.agios.com.